BCI
TGTX icon

Brinker Capital Investments’s TG Therapeutics TGTX Stock Holding History

Brinker Capital Investments’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Buy
+5,561
New +$228K ﹤0.01% 1630
2021
Q1 		– Sell
-7,864
Closed -$409K – 1263
2020
Q4 		$409K Buy
+7,864
New +$266K 0.01% 877

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Brinker Capital Investments's TGTX Position: Q2 2026 in Review

Brinker Capital Investments opened a new position in TG Therapeutics (TGTX) in Q2 2026: 5,561 shares worth $306K. The stake represents ﹤0.01% of the portfolio and ranks #1630 among its holdings. This is a return to the name: Brinker Capital Investments previously reported a position in TGTX as recently as Q4 2020.

Brinker Capital Investments first reported a position in TGTX in Q4 2020 and has held it in 2 quarters since. The position peaked at $409K in Q4 2020. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Brinker Capital Investments held 5,561 shares of TG Therapeutics worth $306K as of Q2 2026.
  • TG Therapeutics was a new Brinker Capital Investments position in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1630 holding.
  • Brinker Capital Investments first reported a position in TG Therapeutics in Q4 2020 and has held it in 2 quarters since.
  • Brinker Capital Investments's TG Therapeutics position peaked at $409K in Q4 2020.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.